Using cognitive decline in novel trial designs for primary prevention and early disease-modifying therapy trials of Alzheimer's disease
Background: Ideally putative disease-modifying therapies for Alzheimer's disease (AD) should be tested in patients who have minimal morbidity. Current barriers to such trials in early disease include the lack of disease-specific early biomarkers, insensitivity of quantitative cognitive outcome measures, and expensive trial designs requiring large sample sizes and long duration. This paper describes principles and progress towards a novel trial design that overcomes these problems, utilizing...[Show more]
|Collections||ANU Research Publications|
|01_Darby_Using_cognitive_decline_in_2011.pdf||181.94 kB||Adobe PDF||Request a copy|
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.